Usage of the CD36-neutralizing antibodies to inhibit fatty acid receptor CD36 leads to therapeutically suppression of tumor growth and metastasis in oral squamous cell carcinomas (Pascual et al., 2017). The gene discussed is CD36; the disease is neoplasm.